ReviewACS applied bio materials2026
Advances in Biomaterial-Based Cardiac Organoids Engineering for Modeling Development and Congenital Heart Defects.
Review in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Human cardiac organoids have emerged as transformative platforms that bridge the gap between reductionist 2D cultures and poorly predictive animal models. By recapitulating the three-dimensional tissue architecture, multicellular composition, and developmental dynamics of the human heart, these systems enable mechanistic studies of heart development and congenital heart disease. This review surveys the bioengineering strategies underlying cardiac organoid generation, with an emphasis on how biomaterial-based approaches enhance organoid fidelity, functional maturation, and experimental reproducibility. We discuss how specific material platforms, spanning Matrigel encapsulation, natural and decellularized extracellular matrix hydrogels, and synthetic polymer networks, translate defined mechanical, biochemical, and structural cues into functional advances in vascularization, cardiomyocyte maturation, and scalable organoid production. A comparative framework is provided across all platform types to guide material selection for cardiac organoid culture and engineering. Applications of biomaterial-supported cardiac organoids in modeling human cardiogenesis and congenital heart defects, as well as in developmental cardiotoxicity screening, are reviewed in depth. Furthermore, we discuss persistent challenges in organoid maturation, vascularization, and standardization and outline future directions integrating advanced biomaterials, organ-on-chip systems, and artificial intelligence-driven analytics to enable next-generation human cardiac models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.